Patent classifications
C12Y304/24069
SNAP-25 REPORTER CONSTRUCTS AND METHODS OF USING THE SAME
The present disclosure relates generally to peptide reporter constructs of SNAP-25, which are useful in determining the activity of botulinum toxins, and methods of using the same.
METHOD OF PURIFYING BOTULINUM TOXIN
Disclosed is a method of purifying a botulinum toxin comprising (a) pre-treating a culture solution containing a botulinum toxin, (b) purifying the pre-treated botulinum toxin using cation exchange chromatography, (c) purifying the botulinum toxin using hydrophobic chromatography, and (d) purifying the botulinum toxin using anion exchange chromatography. The method is capable of purifying a botulinum toxin with high purity and activity and is thus useful for botulinum toxin production.
METHODS OF TREATING MUSCULOSKELETAL DEFORMITIES IN QUADRUPED ANIMALS
Methods of treating musculoskeletal deformities of an anatomical structure in a quadruped animal with botulinum toxin are described. Such deformities can be rotational or flexural. Such deformities can be acquired or congenital. Such anatomical structures include a limb, neck, torso, and/or pelvis of the quadruped animal.
METHOD OF PREPARING TOXIN
Disclosed are a medium composition for culturing Clostridium botulinum comprising a potato peptone, a yeast extract and glucose, and a method of preparing a botulinum toxin using the same. The medium excludes animal-derived products and major allergens, and enables the botulinum toxin-producing strain to reach the maximum growth level within a short time, thereby providing effects of shortening the production time and reducing the production cost in the botulinum toxin production process.
METHOD OF PURIFYING BOTULINUM TOXIN
Disclosed is a method of purifying a botulinum toxin including (a) pre-treating a culture solution containing a botulinum toxin, (b) purifying the pre-treated botulinum toxin using anion exchange chromatography and (c) purifying the botulinum toxin using cation exchange chromatography. The method is capable of purifying a botulinum toxin with high purity and activity using a simple process including anion exchange chromatography and cation exchange chromatography, and is thus useful for botulinum toxin production.
Recombinant clostridial neurotoxins with increased duration of effect
This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.
Botulinum neurotoxins with modified light chain specificity and methods for producing same
A protease directed to a non-neuronal SNARE protein is described. The protease is produced by selective mutation of a botulinum neurotoxin light chain, and is characterized utilizing a reporting construct that includes all or part of the non-neuronal SNARE protein. Such a protease has utility in the treatment of diseases associated with hypersecretion, where the hypersecretion is mediated by a non-neuronal SNARE protein.
NOVEL BOTULINUM NEUROTOXIN AND ITS DERIVATIVES
Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.
Albumin-free botulinum toxin formulations
This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.
NON-CLEAVABLE SUBSTANCE P CONJUGATES AND METHODS OF USE THEREOF
Described herein are methods for treating disorders that relate to neurons that express the neurokinin-1 receptor (NK-1R) in a subject which comprises administering to the subject an effective amount of the pharmaceutical composition of the non-cleavable conjugate comprising a molecule that is recognized and internalized by the NK-1R, and a molecule that is taken inside the cell to kill or temporarily alter the cell.